Summary of Changes for February 2019

This page contains information on changes to the MBS that occurred during February 2019.

Page last updated: 23 November 2020

Summary of Item Changes

New item

Description amended

Amended note

EGFR Test for access to osimertinib for NSCLC patients
A test of tumour tissue from a patient with locally advanced or metastatic NSCLC to determine if the requirements relating to EGFR T790M gene status for access to osimertinib under othe PBS.

Remove specialist restriction from item 42505
'S' removed from item 42505